GlassScriptPhysician profile
Danielle Dubois
NPI 1932683182
$340.06
in general payments reported to CMS, 2019-2025
10 companies · $82.31 in 2025
The $82.31 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $74.62 · 2023: $48.98 · 2024: $134 · 2025: $82.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $265.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $74.62 | 2022 | |
| Novo Nordisk INC | $46.25 | 2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $45.93 | 2023-2024 | Austedo Xr |
| Dexcom, INC. | $32.65 | 2024 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $29.50 | 2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $28.25 | 2024 | Rexulti |
| Rigel Pharmaceuticals, INC. | $27.30 | 2023 | Tavalisse, Rezlidhia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.50 | 2024 | Caplyta |
| Indivior INC. | $18.06 | 2025 | Sublocade |
| Collegium Pharmaceutical, INC. | $18.00 | 2025 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Dubois listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.